Disc Medicine, Inc.IRON

Disc Medicine, Inc. is a clinical-stage biotech chasing therapies for haematological diseases, a field where the science evolves faster than the balance sheet. The company’s latest SEC filing shows a quarter to 31 March that was heavy on science and light on sales: net loss of $63.5 million, operating loss of $69.5 million, and negative diluted EPS of $1.65 on 38.5 million shares. The cash position stood at $88.9 million, but the operating cash burn was $62.2 million, meaning the company is haemorrhaging cash while maintaining a ledger that still looks solvent on paper. The filing does not explain how long that $88.9 million will last if the burn rate persists, and the 10-Q offers no guidance on runway or next milestones.

Disc’s pipeline is built around product candidates that remain pre-clinical or early-stage, and the company candidly admits its approach ‘may never lead to approved or marketable products.’ That is the most honest line in the entire filing, and it appears on page 10 of the 10-Q. The company’s most concrete near-term obligation is a licence with Roche that triggers milestone payments of up to $120 million based on hypothetical future sales of licensed products. In other words, Disc’s balance sheet is underwriting a bet on drugs that have not cleared safety trials, let alone reached patients. The filing also states that the company is obligated to pay Roche up to $18 million, $45 million, and $87.5 million on a product-by-product basis, contingent on development and commercialisation thresholds that have not been met.

The 10-Q for the quarter ending 31 March 2026 is the latest filed document and contains the financials, R&D expense of $45.9 million, zero capex, and a stockholders’ equity figure of $688.4 million that is almost entirely intangible. Assets total $750.2 million but liabilities are a modest $61.8 million, so the balance sheet is structurally simple: cash is melting, equity is large, and debt is small. There is no revenue line because Disc has not yet sold a therapy, and the 10-Q warns that the programmes ‘are subject to significant risks and uncertainties,’ a phrase that usually accompanies an experimental asset. The company’s insiders have filed three Forms 4 and two Forms 144 in the last fortnight, all marked as routine sales of shares, not new financing.

The company’s SEC submissions index confirms the pace of filings but adds no new financial data, and the companyfacts JSON shows no surprises beyond what is already in the 10-Q. There is no earnings call transcript, no segment breakdown, and no forward-looking guidance-only a blunt admission that the science may fail. Investors who want to see Disc Medicine’s path to profitability will not find a roadmap in the filings; they will find a ledger that keeps subtracting and a licence that obligates payments if, and only if, the drugs ever work.

For those tracking the company’s progress, the SEC EDGAR index is the primary rail, and the 10-Q remains the definitive source. There is no chart rail or valuation commentary in the evidence, so any attempt to anchor a view to a technical level or valuation model would be invention. The next catalyst would be a published clinical update, a regulatory meeting, or a cash infusion; none of these events are evidenced in the current source pack. The central tension is simple: Disc’s science is early, its cash is melting, and its obligations are written in conditional clauses that read like a scientist’s worst-case scenario. Until the data changes, the balance sheet is the only thing standing between the company and a going-concern warning.